Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe.
Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Trials group; Adamides T, Akkerman O, Andersen AB, Bakos Á, Bjarnason A, Bruchfeld J, Chesov D, Codecasa LR, Cirillo D, Danilovits M, Davidavičienė E, Duarte R, De Souza Galvão ML, Garnier S, Gjocaj M, Günther G, Ibraim E, Kappnik M, Khachatryan N, Klimuk D, Kuksa L, Jachym MF, Josefsdottir K, Kaluzhenina A, Lange C, Mack U, Makek MJ, Manika K, Mclaughlin AM, Mema D, Mengshoel AT, Muylle I, Nanovic Z, Özkara Ş, Perl S, Pesut D, Pierdou D, Ryskulov G, Skowroński M, Solovic I, Sukholytka M, Svetina P, Terleeva Y, Tiberi S, Togonidze T, Torri S, Turaev L, Usmanova R, Wirtz G, Vasankari T, Zhdanova E.
Günther G, et al. Among authors: de souza galvao ml.
Clin Microbiol Infect. 2024 Mar 13:S1198-743X(24)00121-6. doi: 10.1016/j.cmi.2024.03.009. Online ahead of print.
Clin Microbiol Infect. 2024.
PMID: 38490355